Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25040429 | 0.95 | MEN1 (0.46) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL874176 | 0.87 | POLB (0.52) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL7006941 | 0.87 | HTT (0.54) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL5500527 | 0.85 | HTT (0.53) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL17854642 | 0.85 | MAPT (0.46) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL14418100 | 0.85 | HTT (0.55) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL8263297 | 0.84 | MEN1 (0.55) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL13168044 | 0.84 | PKM (0.50) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL2333730 | 0.84 | HTT (0.59) | KMT2APKMMEN1HTTPOLB | |
| SCHEMBL10118722 | 0.83 | PKM (0.49) | KMT2APKMMEN1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| CN-114761025-A | PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes | 施明哲 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | KMT2A 4291/4885PKM 1342/4885MEN1 4187/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | KMT2A 3652/4885PKM 1864/4885MEN1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.